A Phase 1 interventional study of BMS-986504 and [14C]-BMS-986504 in Advanced Solid Tumors With Homozygous MTAP Deletion, sponsored by Bristol-Myers Squibb. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of [14C]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Participants will receive a single oral dose of radiolabeled \[14C\]-BMS-986504 on C1D1. Part B: Participants will receive non-radiolabeled BMS-986504, starting from C1D1 and until criteria for treatment discontinuation are met.
Drug: BMS-986504 · Drug: [14C]-BMS-986504
Specified dose on specified days
Specified dose on specified days
Maximum observed concentration (Cmax)
Time frame: Up to 2 weeks
Time of maximum observed drug concentration (Tmax)
Time frame: Up to 2 weeks
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))
Time frame: Up to 2 weeks
Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Time frame: Up to 2 weeks
Terminal elimination half-life (T-HALF)
Time frame: Up to 2 weeks
Apparent total body clearance (CLT/F)
Time frame: Up to 2 weeks
Apparent volume of distribution during the terminal phase (Vz/F)
Time frame: Up to 2 weeks
Percentage of estimated part for the calculation of AUC(INF) (%AUC(INF))
Time frame: Up to 2 weeks
Blood-to-plasma total radioactivity (TRA) ratio
Time frame: Up to 2 weeks
Total amount of administered dose recovered in urine (UR)
Time frame: Up to 2 weeks
Percent of administered dose recovered in urine (%UR)
Time frame: Up to 2 weeks
Renal clearance (CLR) in urine
Time frame: Up to 2 weeks
Total radioactivity in UR
Time frame: Up to 2 weeks
Total radioactivity in %UR
Time frame: Up to 2 weeks
Total radioactivity in total amount of administered dose recovered in feces (FR)
Time frame: Up to 2 weeks
Total radioactivity in percent of administered dose recovered in feces (%FR)
Time frame: Up to 2 weeks
Total amount of radioactivity recovered (Rtotal)
Time frame: Up to 2 weeks
Total percent of radioactivity recovered (%TOTAL)
Time frame: Up to 2 weeks
TRA amount recovered and fraction of the radioactive dose in vomit if applicable
Time frame: Up to 2 weeks
Number of participants with adverse events (AEs)
Time frame: Up to 2 years
Number of participants with serious adverse events (SAEs)
Time frame: Up to 2 years
Number of participants with AEs leading to discontinuation
Time frame: Up to 2 years
Number of participants with drug-related AEs
Time frame: Up to 2 years
Number of participants with laboratory abnormalities
Time frame: Up to 2 years
Number of deaths
Time frame: Up to 2 years
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Mar 2025 (actual). Primary completion is estimated for Oct 2027, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Navlimetostat